{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:32:06Z","timestamp":1707525126201},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,29]]},"DOI":"10.7759\/cureus.41164","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T06:53:20Z","timestamp":1688108000000},"source":"Crossref","is-referenced-by-count":0,"title":["Appearances of Premature Atrial and Ventricular Contractions After Switching From Brand Name to Generic Cibenzoline"],"prefix":"10.7759","author":[{"given":"Gaku","family":"Oguri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhito","family":"Fujiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.02.071","article-title":"Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation","volume":"93","author":"Amit G","year":"2004","unstructured":"Amit G, Rosen A, Wagshal AB, et al.. Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation. Am J Cardiol. 2004, 93:1558-60. 10.1016\/j.amjcard.2004.02.071","journal-title":"Am J Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0167-5273(98)00053-9","article-title":"Safety and tolerability of intravenous cibenzoline for acute termination of spontaneous sustained ventricular tachycardia: Cibenzoline and spontaneous VT","volume":"64","author":"Chevalier P","year":"1998","unstructured":"Chevalier P, Dacosta A, Chalvidan T, Bonnefoy E, Kirkorian G, Isaaz K, Touboul P. Safety and tolerability of intravenous cibenzoline for acute termination of spontaneous sustained ventricular tachycardia: Cibenzoline and spontaneous VT. Int J Cardiol. 1998, 64:265-70. 10.1016\/s0167-5273(98)00053-9","journal-title":"Int J Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199243050-00008","article-title":"Cibenzoline: a review of its pharmacological properties and therapeutic potential in arrhythmias","volume":"43","author":"Harron DW","year":"1992","unstructured":"Harron DW, Brogden RN, Faulds D, Fitton A. Cibenzoline: a review of its pharmacological properties and therapeutic potential in arrhythmias. Drugs. 1992, 43:734-59. 10.2165\/00003495-199243050-00008","journal-title":"Drugs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.758","article-title":"Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis","volume":"300","author":"Kesselheim AS","year":"2008","unstructured":"Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008, 300:2514-26. 10.1001\/jama.2008.758","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/00001573-200101000-00004","article-title":"Issues in the use of generic antiarrhythmic drugs","volume":"16","author":"Reiffel JA","year":"2001","unstructured":"Reiffel JA. Issues in the use of generic antiarrhythmic drugs. Curr Opin Cardiol. 2001, 16:23-9. 10.1097\/00001573-200101000-00004","journal-title":"Curr Opin Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(00)00715-3","article-title":"Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias","volume":"85","author":"Reiffel JA","year":"2000","unstructured":"Reiffel JA, Kowey PR. Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias. Am J Cardiol. 2000, 85:1151-3. 10.1016\/s0002-9149(00)00715-3","journal-title":"Am J Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.101800","article-title":"Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations","volume":"183","author":"Tsadok MA","year":"2011","unstructured":"Tsadok MA, Jackevicius CA, Rahme E, et al.. Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations. CMAJ. 2011, 183:E817-23. 10.1503\/cmaj.101800","journal-title":"CMAJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1968.03150080025004","article-title":"The generic inequivalence of drugs","volume":"206","author":"Varley AB","year":"1968","unstructured":"Varley AB. The generic inequivalence of drugs. JAMA. 1968, 206:1745-8. 10.1001\/jama.1968.03150080025004","journal-title":"JAMA"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/165586-appearances-of-premature-atrial-and-ventricular-contractions-after-switching-from-brand-name-to-generic-cibenzoline","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:00:55Z","timestamp":1707508855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/165586-appearances-of-premature-atrial-and-ventricular-contractions-after-switching-from-brand-name-to-generic-cibenzoline"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.41164","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,29]]}}}